Company: HMDCF
Filing Date: 2025-03-19
Form Type: 20-F
Source: 0001410578-25-000377
Chunk: 554

Company: HUTCHMED (China) Ltd
Filing Date: 2025-03-19
Form: 20-F
Item: Item 5
Chunk 554
---
          %    
Revenue                              ​   ​         ​    ​       ​    ​         ​    ​       ​    ​         ​    ​    
Other Ventures:                      ​   ​         ​    ​       ​    ​         ​    ​       ​    ​         ​    ​    
Shanghai Hutchison Pharmaceuticals   ​   393,525   ​    100.0   ​    385,483   ​    100.0   ​    370,600   ​    100.0
​
The following table shows the amount of equity in earnings of equity investees, net of tax, of our non-consolidated joint ventures for the years indicated.

                        ​                            ​     ​      ​      ​     ​      ​      ​      ​     ​      ​      ​      ​  
----------------------------------------------------------------------------------------------------------------------------------
​                                                    ​   Year Ended December 31,                                                  
​                                                    ​   2024                  ​    2023                  ​    2022               
​                                                        $’000         %            $’000         %            $’000         %    
Equity in earnings of equity investees, net of tax   ​   ​        ​    ​       ​    ​        ​    ​       ​    ​        ​    ​    
Other Ventures:                                      ​   ​        ​    ​       ​    ​        ​    ​       ​    ​        ​    ​    
Shanghai Hutchison Pharmaceuticals                   ​   46,469   ​    100.0   ​    47,295   ​    100.0   ​    49,748   ​    100.0
Oncology/Immunology:                                 ​   ​        ​    ​       ​    ​        ​    ​       ​    ​        ​    ​    
Others                                               ​   —        ​    —       ​    —        ​    —       ​    5        ​    —    
Total                                                ​   46,469   ​    100.0   ​    47,295   ​    100.0   ​    49,753   ​    100.0
​
Investments in equity investees mainly consisted of our investment in Shanghai Hutchison Pharmaceuticals. The fluctuation in the investments in equity investees was primarily due to recording our equity in earnings of Shanghai Hutchison Pharmaceuticals, net of tax, offset by dividends declared.
The following table shows our investment in our equity investee as of the dates indicated.
​

                ​